developsTreatmentFor
P69333
predicate
Indicates that one entity creates or advances a medical or therapeutic intervention intended to address a condition, disease, or problem affecting another entity.
All labels observed (4)
| Label | Occurrences |
|---|---|
| developsTreatmentFor canonical | 27 |
| developedForTreatmentOf | 1 |
| treatmentDevelopedClass | 1 |
| treatmentDevelopedIs | 1 |
Description generation (PDg)
The one-sentence description above was generated by prompting gpt-5.1 with the predicate name and this instruction.
Instruction
Given a predicate that represents a relationship or action between entities, generate a one-sentence description explaining its meaning. # Instructions Focus on describing the relationship, not the entities themselves. # Response Format Begin the description with \' Indicates...\'
Input
Predicate: developsTreatmentFor
Generated description
Indicates that one entity creates or advances a medical or therapeutic intervention intended to address a condition, disease, or problem affecting another entity.
Sample triples (30)
| Subject | Object |
|---|---|
| Regeneron Pharmaceuticals | age-related macular degeneration ⓘ |
| Regeneron Pharmaceuticals | diabetic macular edema ⓘ |
| Regeneron Pharmaceuticals | atopic dermatitis ⓘ |
| Regeneron Pharmaceuticals | asthma ⓘ |
| Regeneron Pharmaceuticals | cancer ⓘ |
| Regeneron Pharmaceuticals | inflammatory diseases ⓘ |
| Regeneron Pharmaceuticals | COVID-19 ⓘ |
| Ridgeback Biotherapeutics | Ebola virus disease NERFINISHED ⓘ |
| Ridgeback Biotherapeutics | COVID-19 NERFINISHED ⓘ |
| Ridgeback Biotherapeutics | serious infectious diseases ⓘ |
| Alexion Pharmaceuticals | paroxysmal nocturnal hemoglobinuria ⓘ |
| Alexion Pharmaceuticals | atypical hemolytic uremic syndrome ⓘ |
| Alexion Pharmaceuticals | generalized myasthenia gravis ⓘ |
| Alexion Pharmaceuticals | neuromyelitis optica spectrum disorder NERFINISHED ⓘ |
| Alexion Pharmaceuticals | hypophosphatasia ⓘ |
| Alexion Pharmaceuticals | lysosomal acid lipase deficiency ⓘ |
| Genzyme | Gaucher disease NERFINISHED ⓘ |
| Genzyme | Fabry disease ⓘ |
| Genzyme | Pompe disease NERFINISHED ⓘ |
| Genzyme | multiple sclerosis ⓘ |
| Genzyme | chronic kidney disease ⓘ |
| BioMarin Pharmaceutical | mucopolysaccharidosis I ⓘ |
| BioMarin Pharmaceutical | mucopolysaccharidosis VI ⓘ |
| BioMarin Pharmaceutical | mucopolysaccharidosis IVA NERFINISHED ⓘ |
| BioMarin Pharmaceutical | phenylketonuria ⓘ |
| BioMarin Pharmaceutical | CLN2 disease ⓘ |
| BioMarin Pharmaceutical | achondroplasia ⓘ |
| Augusto Odone | adrenoleukodystrophy via predicate surface "developedForTreatmentOf" ⓘ |
| Augusto Odone | mixture of oleic acid and erucic acid via predicate surface "treatmentDevelopedIs" ⓘ |
| Augusto Odone | dietary therapy via predicate surface "treatmentDevelopedClass" ⓘ |